What does blinding accomplish in a trial?

• A. Blinding is optional in most trials.
• B. Blinding reduces or minimizes the risk of biased study outcomes.
• C. Blinding should never be used in pharmacodynamic studies.
• D. Blinding increases the risk of bias.

Answer: (B)

Blinding prevents knowledge of which treatment a participant received from influencing behavior, care, and outcome assessment, protecting the trial from bias. When those involved don’t know the allocation, expectations, placebo effects, and observer or measurement biases are less likely to color results, making differences more truly due to the treatment itself. Double-blind designs—where both participants and those who assess outcomes are unaware—are especially effective for safeguarding subjective outcomes, though single-blind designs still reduce some biases. Blinding is not just optional in most trials; it’s a key method to maintain internal validity. It’s also not correct to say it should never be used in pharmacodynamic studies—blinding can be appropriate depending on endpoints and design. And blinding does not increase bias; it aims to minimize it.